---
title: "Cytokine Modulators"
ocid: "ocds-r6ebe6-0000557325"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000557325"
markdown_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000557325.md"
json_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000557325.json"
source: "Public Contracts Scotland"
current_stage: "Award"
buyer: "THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (\"THE AUTHORITY\")"
published: "2018-12-13"
---

# Cytokine Modulators

Buyer: THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ("THE AUTHORITY")  
Current stage: Award  
OCID: ocds-r6ebe6-0000557325

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000557325)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-r6ebe6-0000557325.json)

## Summary

The procurement process pertains to the NHS National Services Scotland, focusing on the tender titled "Cytokine Modulators" within the health industry category. Located in Edinburgh, the procurement is currently at the award stage, with completed contracts for multiple lots awarded. Key dates include the bid submission deadline, which was set for 25 October 2018, with contracts signed on 19 November 2018. This open procurement method allows a range of suppliers to participate in providing specified goods.

This tender creates significant opportunities for businesses operating within the pharmaceutical and healthcare sectors, particularly those specialising in the supply of Anti-TNF agents and related therapies. Companies capable of meeting the rigorous compliance and quality standards outlined in the tender documentation, particularly those with valid UK or EMA Marketing Authorisations, will be well-suited for competition. Businesses of varying sizes that can provide innovative solutions and reliable supply chains are encouraged to explore these opportunities, as the framework covers an extensive range of essential health products for NHS Scotland.

## Notice

The Framework Agreement is for the supply and delivery of the following Anti-TNF agents and associated dual therapy medicines to health boards across NHS Scotland: Etanercept Infliximab Methotrexate The Goods have been split into five (5) categories, each of which are identified as a "Lot". Full details of each Lots are contained in section II.2 of this notice.

### Lot Information

Etanercept

This Lot is for the supply of Etanercept 10mg, 25mg, 50mg presentations to NHS Scotland. This will require supply of the Goods direct to hospitals and nominated home delivery supplier(s) as directed by the Authority. Each product line has been treated as an individual Lot and is awarded on a line by line basis. This Lot was awarded as an unranked multi supplier Framework to three (3) suppliers.

Renewal: The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

Infliximab

This Lot is for the supply Infliximab 100mg powder for concentrate for solution for infusion to NHS Scotland. This Lot has been awarded as an unranked multi supplier Framework and awarded to five (5) suppliers.

Renewal: The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

Methotrexate (50 mg per 1 ml concentration ) pre-filled self injection device

This Lot is for the supply of Methotrexate (50 mg per 1 ml concentration ) pre-filled self injection device to NHS Scotland. This will require supply of the Goods direct to hospitals and nominated home delivery supplier(s) as directed by the Authority. The Authority has awarded as an unranked multi-supplier Framework Agreement for the Lot to two (2) suppliers.

Renewal: The Authority is entitled at its sole discretion to extend the Framework Agreement of up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

Methotrexate (25 mg per 1 ml concentration ) pre-filled syringes

This Lot is for the supply of Methotrexate (25 mg per 1 ml concentration ) pre-filled syringes to NHS Scotland. This will require supply of the Goods direct to hospitals and nominated home delivery supplier(s) as directed by the Authority. The Authority has awarded a an unranked multi-supplier Framework Agreement for the Lot and to one (1) supplier.

Renewal: The Authority is entitled at its sole discretion to extend the Framework Agreement of up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

Methotrexate (25 mg per 1 ml concentration ) pre-filled self injection device

This Lot is for the supply of Methotrexate (25 mg per 1 ml concentration ) pre-filled self injection device to NHS Scotland. This will require supply of the Goods direct to hospitals and nominated home delivery supplier(s) as directed by the Authority. The Authority has awarded a an unranked multi-supplier Framework Agreement for the Lot and to one (1) supplier.

Renewal: The Authority is entitled at its sole discretion to extend the Framework Agreement of up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Public Contracts Scotland |
| Latest notice | https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=DEC340063 |
| Notice type | OJEU - F3 - Contract Award Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large |
| All stages | Tender, Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 13 Dec 2018 |
| Submission deadline | 24 Oct 2018 |
| Future notice date | Not specified |
| Award date | 19 Nov 2018 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £107,012,831 |
| Lots value | £106,967,156 |
| Awards value | Not specified |
| Contracts value | £89,735,964 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Complete |
| Awards status | Not specified |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ("THE AUTHORITY") |
| Locality | EDINBURGH |
| Post town | Edinburgh |
| Postcode | EH12 9EB |
| Country | Scotland |
| ITL 1 | TLM Scotland |
| ITL 2 | TLM1 East Central Scotland |
| ITL 3 | TLM13 City of Edinburgh |
| Local authority | City of Edinburgh |
| Electoral ward | Drum Brae/Gyle |
| Westminster constituency | Edinburgh South West |
| Delivery location | TLM Scotland |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 8 |
| Supplier names | ACCORD HEALTHCARE; BIOGEN IDEC; MEDAC PHARMA; MSD; NAPP PHARMACEUTICALS; NORDIC PHARMA; PFIZER; SANDOZ |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products

## Release History

- 13 Dec 2018 at 00:00 - Award - OJEU - F3 - Contract Award Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=DEC340063
- 26 Sep 2018 at 00:00 - TenderUpdate - OJEU - F14 - Corrigendum - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=SEP332565
- 20 Sep 2018 at 00:00 - Tender - OJEU - F2 - Contract Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=SEP332008

## Documents

- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=SEP332008
  Cytokine Modulators - The Framework Agreement is for the supply and delivery of the following Anti-TNF agents and associated dual therapy medicines to health boards across NHS Scotland: Etanercept Infliximab Methotrexate The Goods have been split into five (5) categories, each of which are identified as a "Lot". Full details of each Lot are contained in section II.2 of this notice.
- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=DEC340063
  Cytokine Modulators - The Framework Agreement is for the supply and delivery of the following Anti-TNF agents and associated dual therapy medicines to health boards across NHS Scotland: Etanercept Infliximab Methotrexate The Goods have been split into five (5) categories, each of which are identified as a "Lot". Full details of each Lots are contained in section II.2 of this notice.

## Notice URLs

- http://
- http://www.nhsscotlandprocurement.scot.nhs.uk/
- https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000557325
- https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000557325. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-r6ebe6-0000557325.json.